iuvo was founded in 1978 as Sterilization Testing Services (STS), which provided ethylene oxide sterilization services along with associated ethylene oxide residual analysis, microbiology testing, and in vivo toxicology testing. 


Ethox International, a medical device manufacturing firm located in Buffalo, NY, purchased STS in 2002. At this time, the company had acquired a packaging facility suitable for medical device work. The packaging business was incorporated into the Buffalo operation, and the ethylene oxide sterilization portion of the business became part of a modern sterilization facility that was a wholly owned subsidiary of Ethox and was relocated to Erie, PA.  The laboratory functions of the two companies were then consolidated in Rush, NY.


Ethox International was purchased by Moog, Inc. in January of 2009, and became part of the Moog Medical Devices business group until June of 2013, at which time Ethox International was sold. Under Moog, the Life Science laboratory facility was renamed MMDR, Inc., and the ethylene oxide sterilization facility was MMC Sterilization Services Group, Inc. (MMC). 


iuvo was founded in March 2015 through the acquisition of the MMDR and MMC business segments from Moog, Inc.  In 2016, iuvo divested the sterilization portion of the business, selling it to Cosmed Group, Inc. and maintains a partnership with Cosmed, providing laboratory services for the sterilization business in addition to directly for customers in the medical device and pharmaceutical industries. 


In July 2018, iuvo acquired Oculos Clinical Research, a leader in ophthalmic clinical research. The transaction combined iuvo’s already extensive preclinical testing expertise – already strong in the ophthalmic space – with the clinical trial management capabilities of Oculos. This helped to establish iuvo as a truly integrated development organization which would help iuvo’s clients improve speed to market of products in the development pipeline, including OTCs, drugs, devices, and combination products.


On September 30, 2022, iuvo BioScience was acquired by Ampersand Capital Partners, a private equity firm specializing in growth equity investments in the life science and healthcare sectors. Ampersand’s investment supports the expansion of iuvo’s integrated service portfolio and laboratory capacity.


On January 18, 2024, iuvo expanded its clinical research capabilities with the acquisition of Promedica International (PMI), a specialty ophthalmology focused clinical CRO. The combined organization supports all aspects of ophthalmic clinical research, from front of eye to back of the eye, leveraging an even larger team of experts with centuries of collective experience on ophthalmology. Through the combination of the two companies, iuvo and PMI became the only niched ophthalmology service provider able to support customers from the early pre-clinical and laboratory stages through all phases of clinical development within one integrated organization.

Throughout the 40+ years of history of the company, iuvo has maintained long lasting relationships with its customers due to its impeccable service and its connection to the needs of each individual business.